Status:
COMPLETED
Dexmedetomidine and Liver Transplantation
Lead Sponsor:
RenJi Hospital
Conditions:
Dexmedetomidine, Liver Transplantation, Allograft Function, Survival
Eligibility:
All Genders
18-65 years
Phase:
EARLY_PHASE1
Brief Summary
1.1. Background 1.1.1. Perioperative ischaemia/reperfusion (I/R) injury during liver transplantation is strongly associated with early allograft dysfunction, graft loss, and mortality. 1.1.2. Hepatic...
Eligibility Criteria
Inclusion
- Age 18-65 years
- Scheduled to undergo allogenic liver transplant(DCD/DBD) surgery under general anaesthesia
- Patients should meet the UCSF criteria
- Agree to participate and give written informed consent
Exclusion
- Severe renal dysfunction (undergoing renal replacement therapy before surgery)
- Severe pulmonary dysfunction (including pneumonia, atelectasis, pleural effusion, acute lung injury or ARDS)
- Severe circulatory instability (severe coronary artery disease, unstable angina, left ventricular ejection fraction \< 30%, sick sinus syndrome, severe sinus bradycardia \[\< 50 bpm\], second-degree or greater atrioventricular block)
- Known allergy or intolerance to trial medication
- Refusal to participate in the study
- Participation in other clinical trials within 30 days prior to randomisation.
- Retransplantation
- Multiple organ transplantation
- Other reasons that are considered unsuitable for study participation by the responsible surgeon or anaesthetist (reasons must be documented in the case report form \[CRF\])
Key Trial Info
Start Date :
January 14 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
330 Patients enrolled
Trial Details
Trial ID
NCT03770130
Start Date
January 14 2019
End Date
December 31 2022
Last Update
August 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Renji Hospital, Shanghai Jiao Tong University, School of Medicine
Shanghai, China, 200127